AI assistant
Sending…
Nuvectis Pharma, Inc. — Director's Dealing 2025
Oct 29, 2025
33912_dirs_2025-10-29_a369112d-5779-4f9f-8c9f-a0627dd1420b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2025-10-23
Reporting Person: Mosseri Marlio Charles (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-10-23 | Common Stock | P | 46900 | $6.06 | Acquired | 3028706 | Indirect |
| 2025-10-24 | Common Stock | P | 35034 | $6.15 | Acquired | 3063740 | Indirect |
| 2025-10-27 | Common Stock | P | 72836 | $6.28 | Acquired | 3136576 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 109321 | Direct |
Footnotes
F1: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL SPF.
More from Nuvectis Pharma, Inc.
Interim / Quarterly Report
2026
May 5
Earnings Release
2026
May 5
Regulatory Filings
2026
Feb 23
Capital/Financing Update
2026
Feb 13
Earnings Release
2026
Feb 11
Annual Report
2026
Feb 11
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9